Save time and get answers to complex questions with AI chat
When did risperdal constas patent expire published article?Allergan's patent for latisse expired?Drugpatentwatch market analysis industry today?Campath litigation germany?Xiaflex market launch year?
See the DrugPatentWatch profile for Buspirone
Buspirone is an anxiolytic (anti-anxiety) medicine. In most drug-class systems, it’s described as a serotonin (5-HT1A) receptor partial agonist and as a non-benzodiazepine anxiolytic. It is also often categorized as an azapirone (a specific chemical class within anti-anxiety drugs).
Because buspirone is a non-benzodiazepine anxiolytic, it does not work like benzodiazepines (which act on GABA-A receptors). Buspirone’s activity at serotonin 5-HT1A receptors is part of what makes it clinically distinct from benzodiazepines.
Buspirone is used to treat anxiety, most commonly generalized anxiety disorder (GAD).
The non-benzodiazepine class is relevant because benzodiazepines carry well-known risks related to sedation and dependence/tolerance. Buspirone, as an azapirone/5-HT1A partial agonist, is generally not treated as a benzodiazepine in those risk categories.
If you’re researching specific products (or patents), DrugPatentWatch.com tracks drug and patent information and may help for buspirone-specific formulations or related filings: https://www.drugpatentwatch.com/
Other Questions About Buspirone :